WISDOM
22.11.2022 12:18:41 CET | Business Wire | Press release
Wisdom, a social audio app that facilitates one-to-one meaningful conversations, today launches a pioneering new format, ‘Voice Answers’, an asynchronous short-form audio take on the traditional questions and answers format.
Voice Answers was designed to overcome the limitations associated with the live social audio format, popularised by Clubhouse. Now the centerpiece of the app, ‘Voice Answers’ delivers an algorithmically curated feed of wise answers to self-discovery questions like “Describe your idea of a perfect day.” to mentoring questions like “How do I break into the film industry?” to life hack questions like “How do I set boundaries in a relationship?”
Social Audio has demonstrated tremendous promise, with platforms like Clubhouse, Spotify, Twitter, Discord and LinkedIn rolling out social audio experiences to hundreds of millions of users. However, social audio has recently been much maligned, with recent headlines including “Is social audio already dead?” and “The Rise And Fall Of Social Audio.”
Dayo Akinrinade founder and CEO of Wisdom comments: “The biggest challenge with social audio today is its low listening value-to-word ratio. While podcasts are carefully planned and produced, social audio tends to be more freewheeling and, as a result, the content quality is less reliable. Another challenge is the consumption of live audio content being limited to whomever happens to be listening at a given time. Inspired by TikTok’s content-first algorithm and short-video format, my goal with Voice Answers' asynchronous short-form audio format, is to bring elements of TikTok’s innovation to social audio by preserving the excitement of live conversations, whilst also solving the low listening value-to-word ratio problem that's endemic to the live social audio format that Clubhouse pioneered.”
With today’s launch of Voice Answers, the Wisdom app opens to a voice answer, which the user can listen to or swipe. Each swipe informs the machine-learning algorithm, helping improve content recommendations to provide a stream of personalised, high-quality answers.
To be creator-friendly, Voice Answers are restricted to less than 60 seconds and Wisdom auto-generates an audiogram for each Voice Answer, which creators can easily share on other social networks.
Dayo continues: “Questions and answers are powerful tools to unlock insights and gain a deeper understanding of who we are and the world around us. Early in my career, as a black woman in tech, I lacked access to wise people, which hampered my progression. The Voice Answers format is positioned to empower us to share our wisdom with the world, whilst simultaneously pioneering a new short form asynchronous audio format which I hope will overcome the current challenges associated with social audio.”
Download Wisdom for Android on Google Play store here
Download Wisdom for iOS on Apple App Store here
—---- END PRESS RELEASE —--
Notes to the Editor
A selection of supporting hi-res feature images can be found on Google Drive here
About Wisdom
Wisdom is a venture-backed social audio app on a mission to leave the world a bit wiser than we found it. Wisdom connects you for live one-to-one conversations and Q&A, centered on knowledge-sharing and self-discovery. Within a year of launch, Wisdom was awarded Apple’s App Store ‘App of the Day’ twice and TechRadar’s ‘Best Android Apps of 2022’.
Wisdom is a pioneer in the social audio space having created ‘Voice Answers’ an asynchronous, short-form audio take on the traditional Q&A format, which delivers an algorithmically curated feed of high-quality voice answers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005094/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom